Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Advanced
New in RUL
About RUL
In numbers
Help
Sign in
Details
Optimizing patient access to orphan medicinal products: lessons from Central and Eastern Europe
ID
Kluszczynski, Tomasz
(
Author
),
ID
Németh, Bertalan
(
Author
),
ID
Władysiuk, Magdalena
(
Author
),
ID
Czech, Marcin
(
Author
),
ID
Kamusheva, Maria
(
Author
),
ID
Fotin, Nicolae
(
Author
),
ID
Rose, Sandra
(
Author
),
ID
Doležal, Tomáš
(
Author
),
ID
Hren, Rok
(
Author
)
PDF - Presentation file,
Download
(2,08 MB)
MD5: 7ED97C97E4FD5FAAF136B7F9292B33E0
URL - Source URL, Visit
https://www.mdpi.com/2001-6689/13/2/24
Image galllery
Abstract
This study examines patient access to orphan medicinal products (OMPs) in Central and Eastern Europe (CEE) over the past five years, focusing on seven countries: Bulgaria, Czechia, Hungary, Poland, Romania, Slovakia, and Slovenia. While these jurisdictions have undergone rapid healthcare transformations, significant disparities in OMP access persist compared to Western Europe. This study aimed to address this gap by identifying barriers and enablers to optimize patient access to OMPs in a sustainable and equitable manner. A mixed-methodology approach was utilized, combining systematic literature reviews, in-depth interviews, and advisory board insights. Perspectives were gathered from a wide range of stakeholders, including policymakers, payers, academia, industry associations, and patient advocacy groups. Additionally, the study incorporated data from CEE-specific initiatives to triangulate findings and evaluate barriers, enablers, and best practices in OMP access. The analysis identified sub-optimal OMP access across most CEE countries, marked by prolonged delays and lower reimbursement rates compared to Western Europe, with Slovenia and Czechia as notable exceptions. Key barriers include limited awareness, inadequate health technology assessment (HTA) frameworks, insufficient financing mechanisms, underutilization of novel access schemes, and fragmented patient engagement. Conversely, enablers include the presence of rare disease policies, OMP-specific HTA frameworks, and patient-inclusive decision-making processes.
Language:
English
Keywords:
healthcare
,
rare diseases
,
orphan medicinal products
,
patient access
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FMF - Faculty of Mathematics and Physics
Publication status:
Published
Publication version:
Version of Record
Year:
2025
Number of pages:
15 str.
Numbering:
Vol. 13, iss. 2, art. no. 24
PID:
20.500.12556/RUL-169435
UDC:
614:615
ISSN on article:
2001-6689
DOI:
10.3390/jmahp13020024
COBISS.SI-ID:
237516291
Publication date in RUL:
28.05.2025
Views:
317
Downloads:
52
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Journal of market access & health policy
Shortened title:
J. mark. access health policy
Publisher:
Co-Action Publishing, Co-Action Publishing, Taylor & Francis Group, MDPI
ISSN:
2001-6689
COBISS.SI-ID:
524322841
Secondary language
Language:
Slovenian
Keywords:
zdravstvo
,
redke bolezni
,
zdravila sirote
,
dostopnost
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back